Key Takeaways
- ENI (ENI) significantly surpassed analyst expectations for Q3 2025 adjusted net income and operating profit, driven by robust production figures.
- Sanofi (SAN) reported strong Q3 2025 earnings, with business EPS and sales exceeding estimates, notably boosted by Dupixent sales.
- Japan's retail sector presented a mixed picture in September, with Tokyo department store sales rebounding to 2.5% year-over-year growth, while nationwide sales growth slowed to 1.4%.
Italian energy giant ENI (ENI) and French pharmaceutical major Sanofi (SAN) both reported stronger-than-expected third-quarter 2025 earnings, signaling solid operational performance in their respective sectors. Meanwhile, Japan's retail landscape displayed contrasting trends in September, with a rebound in Tokyo department store sales juxtaposed against a slowdown in nationwide growth.
ENI's Strong Q3 Performance
ENI (ENI) delivered a robust third quarter, with adjusted net income reaching €1.25 billion, significantly outperforming analyst estimates of €1.01 billion. The company's adjusted operating profit also exceeded expectations, coming in at €2.07 billion against an estimated €1.89 billion.
This strong financial showing was supported by solid production, which stood at 1.76 million barrels of oil equivalent per day (boe/d), surpassing the estimated 1.72 million boe/d. The Enilive & Plenitude segment contributed €333 million in adjusted operating profit. The company anticipates its full-year production to range between 1.71 million and 1.72 million boe/d.
Sanofi Beats Estimates on Key Metrics
Sanofi (SAN) also posted impressive Q3 2025 results, with business earnings per share (EPS) reported at €2.91, comfortably beating the estimated €2.65. The pharmaceutical firm's business operating income reached €4.45 billion, exceeding the €4.13 billion consensus.
Total sales for the quarter were €12.43 billion, slightly above the €12.36 billion estimate, with sales at constant exchange rates growing by 7%. A significant driver of this growth was Dupixent, Sanofi's key immunology drug, which recorded net product sales of €4.16 billion, surpassing the €4.01 billion estimate. Notably, research and development expenses were €1.83 billion, lower than the anticipated €1.94 billion.
Mixed Signals from Japan's Retail Sector
Japan's department store sales in September presented a nuanced picture of consumer spending. While Tokyo department store sales saw a positive turnaround, growing 2.5% year-over-year, reversing the previous month's -2.3% decline, nationwide sales growth slowed.
Nationwide department store sales increased by 1.4% year-over-year in September, a noticeable deceleration from the 2.6% growth recorded in the previous month. This mixed performance suggests regional variations in consumer confidence and spending patterns across Japan.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.